# Appalachian Node

> **NIH NIH UG1** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $154,576

## Abstract

Project Summary/Abstract
The COVID-19 pandemic caused by SARS-CoV-2 has resulted in social distancing measures, the total
consequences of which, particularly as they relate to substance use and drug overdose deaths, are unknown.
News reports and early studies have suggested increases in opioid overdose deaths. In addition, the pandemic
has also changed how medicine is practiced, with decreased face-to-face visits and a commensurate, albeit
slower, rise in telemedicine. Given that opioid overdose deaths are on the rise in the United States and access
to medications for opioid use disorder (MOUD) was already limited before the pandemic, ensuring access to
addiction treatment is more urgent now than ever. The IQVIA Longitudinal Prescription (IQVIA LRx) database
contains 92% of all prescriptions dispensed nationwide, including buprenorphine formulations. We seek to
utilize this database to understand the impact of COVID-19-related social distancing measures, MOUD
regulatory changes around telemedicine, and unemployment on access to buprenorphine across the entire US.
Our first aim seeks to understand how access to buprenorphine was affected by several policy changes
occurring at specific timepoints, including implementation of social distancing measures and changes in federal
MOUD prescribing guidelines related to telemedicine. We will achieve this by conducting an interrupted time
series with segmented regression analysis to understand the time-varying relationship between buprenorphine
access and events at specific time points. Our second aim seeks to address the impact of insurance coverage
on access to treatment. From March to May 2020, at least 40 million people filed for unemployment in the US.
Given that most people with health insurance receive it through their employer, we anticipate significant
reductions in access to employer-based health insurance coverage. As a result, we hypothesize that patients
with commercial health insurance will have more disruptions in their access to MOUD, specifically
buprenorphine, compared to patients with public insurance (Medicaid/Medicare). These findings will be among
the first to characterize the changes to MOUD prescribing in the setting of COVID-19. In subsequent research,
we will seek to utilize additional datasets to determine the relationship between changes in MOUD access and
opioid-related morbidity and mortality outcomes, including fatal and nonfatal overdoses. Understanding these
relationships will inform best practices for MOUD prescribing to reduce patient harm in the setting of a
pandemic.

## Key facts

- **NIH application ID:** 10331194
- **Project number:** 3UG1DA049436-03S1
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** JUDITH FEINBERG
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $154,576
- **Award type:** 3
- **Project period:** 2019-06-15 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10331194

## Citation

> US National Institutes of Health, RePORTER application 10331194, Appalachian Node (3UG1DA049436-03S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10331194. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*